GHK-Cu and Vascular Repair: Matrix Growth vs Vessel Function
Vascular repair research asks several different questions. Can a vessel dilate more effectively? Can new microvessels form? Can injured tissue rebuild its supporting matrix? The vascular-repair PDF brings these processes together, but its cited studies measure them separately. GHK-Cu and coenzyme Q10 provide a useful comparison of structural repair and vascular function.
GHK-Cu: measuring new matrix inside a wound
In a 1993 experiment, Maquart and colleagues implanted wound chambers beneath the skin of male Sprague-Dawley rats weighing 250–300 g. One experiment delivered 2.0 mg GHK-Cu in 0.2 mL buffer directly into a chamber, beginning seven days after implantation and repeating every three days for another two weeks. Chambers were collected on day 29. The study material was PC 1020, described as a 2:1 peptide-to-copper molar complex. [1]
At day 29, collagen content reached 344% of control, total protein 230%, and glycosaminoglycans 208% (P<0.01 for each). These figures mean percentages of control—not percentage increases. Collagen-degradation products also increased, indicating that matrix turnover accompanied accumulation. [1]
A separate dose-response experiment tested 0.2, 0.5, 1.0, 2.0 and 4.0 mg per chamber in 0.2 mL, every three days during the reported day-7-to-day-23 interval, with collection on day 29. These local rat exposures do not establish a systemic human dose. Matrix accumulation also does not establish scar-free regeneration or restored arterial function. [1]
Endothelial growth: formulation changes the experiment
Wang and colleagues investigated GHK-Cu encapsulated in liposomes in human umbilical-vein endothelial cells and a mouse scald model. The publication reports a 33.1% increase in endothelial-cell proliferation, enhanced VEGF and FGF-2 expression, and stronger CD31 and Ki67 signals in treated burned skin. Angiogenesis was greater with the liposomal preparation than with free GHK-Cu; reported wound-healing time was 14 days after injury. [2]
That is evidence about a particular delivery system in cells and mice. It does not show that free peptide, a different liposome or an injected combination produces the same exposure or result. The accessible primary abstract did not provide a reproducible dose-and-frequency schedule, so none is inferred here. Human-derived endothelial cells are not a human wound-healing trial. [2]
CoQ10: measuring vessel response in people
A double-blind crossover trial studied 23 statin-treated adults with type 2 diabetes and endothelial dysfunction. Participants received oral CoQ10 at 200 mg/day or placebo for 12 weeks, followed by a four-week washout and the alternate treatment. [3]
Compared with placebo, brachial-artery flow-mediated dilation improved by 1.0 ± 0.5 percentage points (mean ± SEM; P=0.04). Nitrate-mediated dilation did not change significantly (P=0.66). This was a functional vascular measurement, not a demonstration of new vessel growth, wound closure or extracellular-matrix reconstruction. The reported CoQ10 preparation should not automatically be relabelled as ubiquinol. [3]
Three outcomes that should stay separate
Matrix measurements describe the material accumulating within injured tissue. Endothelial-cell and angiogenesis experiments examine vascular growth. Flow-mediated dilation examines how an existing artery responds to a stimulus. A positive result in one category does not supply missing results in the others.
The source proposes combining BPC-157, GHK-Cu, KPV and, for severe injury, MGF or PEG-MGF. The studies above did not test that combination or its proposed dosing tiers. Their value is more specific: they identify measurable repair targets and show why formulation, route, model and endpoint must remain attached to every claim.
Related reading: BPC-157 tissue-repair research and vascular function and hypertension.